Clinical trial · Observational
Computational Prediction and Experimental Validation of Gastric Cancer Associated Neoantigens
NCT05498194CI-TRIAL-00060269unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to develop methods for identification of neoantigens from patients with gastric cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Neoantigens | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ratio of predicted neoantigens | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The neoantigen landscape of patients with gastric cancer
- timeFrame
- 3 months from the beginning of the study
- description
- The analysis of tumor DNA and RNA sequencing data will provide the mutational distribution of patients with gastric cancer, which could give rise to neoantigens. Of those, neoantigens derived from hotspot mutations in Vietnamese gastric cancer patients will be identified.
Secondary outcomes (2)
- measure
- The ratio of predicted neoantigens being presented by HLA-I
- timeFrame
- 6 months from the beginning of the study
- description
- Computational pipelines will be employed to predict the pairing of neoantigens and HLA molecules. Subsequently, the ratio of those predicted neoantigens will be validated by co-immunoprecipitation with anti-HLA antibodies and mass spectrometry analysis for their binding to corresponding HLA molecules.
- measure
- The ratio of predicted neoantigens being immunogenic.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or Female patients aged 15 years and older 2. Diagnosed with advanced gastric cancer (T2-4b/N0-3/M0-1 stage, according to the eighth edition of the American Joint Committee on Cancer TNM (AJCC TNM) system) 3. Treatment-Naive 4. Not known for other concomitant cancers 5. Provide written informed consent Exclusion Criteria: 1. Insufficient tumor tissues (less than 1 cm3) 2. Unable to sign informed consent 3. Underwent treatment
References
Publications (0)
Data not yet available
No reference posted for this study.